Northwire Canada EditionFriday, October 16, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4170.10 +1.5% SILVER 57.16 +2.3% COPPER 6.56 −1.5% OIL 97.97 +3.0% PALLADIUM 1136.00 +3.6% LUN 32.91 +0.6% DLP 0.290 −3.3% VCV 0.065 −13.3% GG 2.89 +1.4% NBLC 0.015 +0.0% SF 0.300 −4.8% ATY 0.215 +2.4% GHL 0.060 −7.7% STND 0.060 −7.7% B 0.550 −3.5% HBM 34.33 −0.5% NTR 98.77 −0.7% SGZ 0.035 +0.0% MKA 0.670 +0.0% LXM 0.175 −18.6% CLCH 1.08 −1.8% GOLD 4170.10 +1.5% SILVER 57.16 +2.3% COPPER 6.56 −1.5% OIL 97.97 +3.0% PALLADIUM 1136.00 +3.6% LUN 32.91 +0.6% DLP 0.290 −3.3% VCV 0.065 −13.3% GG 2.89 +1.4% NBLC 0.015 +0.0% SF 0.300 −4.8% ATY 0.215 +2.4% GHL 0.060 −7.7% STND 0.060 −7.7% B 0.550 −3.5% HBM 34.33 −0.5% NTR 98.77 −0.7% SGZ 0.035 +0.0% MKA 0.670 +0.0% LXM 0.175 −18.6% CLCH 1.08 −1.8%
Earnings Routine +

NEUPATH HEALTH REPORTS FIRST QUARTER 2026 RESULTS

NeuPath Health Confirms Growth Trajectory Under New CEO Despite Margin Compression and Debt Settlement Risks

By The Northwire Desk — AI Analysis May 14, 2026 · 07:30 NPTH · 0.56 Neupath Health Inc.
Executive Summary
  • NeuPath Health Inc. reported First Quarter 2026 total revenue of $21.5 million, an 11% increase year-over-year compared to Q1 2025 ($19.3 million).
  • Adjusted EBITDA grew 15% year-over-year to $1.5 million for the period ended March 31, 2026.
  • The Company confirmed the appointment of Stephen Lemieux as Chief Executive Officer, effective April 1, 2026, following a pre-announced transition plan.
  • Clinic revenue reached $20.2 million, driven by increased patient visits and growth in Arthrosamid and fluoroscopy revenues.
  • Gross Margin % decreased slightly to 18.4% from 18.8% in the prior year period.
  • Physical Capacity Utilization increased to 52% from 47% in the prior year period.
  • Cash and cash equivalents stood at $3.5 million as of March 31, 2026.
  • Interest-bearing long-term debt is $6.0 million, resulting in a net debt position of $2.5 million.
  • Basic shares outstanding are 56,180,787 with fully diluted shares at 63,089,211.
Material Impact
  • The Q1 2026 results confirm the growth trajectory previously guided in January 2026 and reported in Q4 2025, indicating consistent execution under new leadership rather than a surprise catalyst.
  • Revenue growth of 11% is positive but shows deceleration compared to the 20% full-year growth achieved in FY 2025, suggesting potential saturation or market headwinds that limit upside materiality.
  • The debt settlement announced April 1, 2026 ($420k owed to former CEO/CFO) remains pending shareholder approval on June 10, 2026; this creates a near-term overhang rather than immediate positive impact.
  • Gross margin compression (18.4% vs 18.8%) is a negative signal regarding cost control or pricing power that offsets the EBITDA growth headline.
  • The stock price has already doubled from $0.21 to ~$0.56 over the past year, largely pricing in this level of performance; therefore, the news lacks the "unexpected" element required for a Material - Positive rating.
NPTH · Price
Company Overview
  • NeuPath Health Inc. operates medical imaging and rehabilitation clinics across Ontario.
  • Flagship operations include physical therapy services, fluoroscopy, and Arthrosamid treatments (a viscosupplementation product for knee osteoarthritis).
  • The business model relies on high utilization of physician shifts and clinic capacity to drive revenue per location.
  • Strategic focus is on expanding the footprint (e.g., Guelph opening) while optimizing existing facility margins.
Read the original news release →

More from Neupath Health Inc.

Apr 01, 2026 · 07:30

NEUPATH HEALTH ANNOUNCES PROPOSED SHARES FOR DEBT SETTLEMENT

Financings Mar 26, 2026 · 07:30

NEUPATH HEALTH REPORTS FOURTH QUARTER AND YEAR-END 2025 RESULTS

Earnings Mar 17, 2026 · 17:02

Neupath Health to release 2025 results March 26

Earnings Jan 26, 2026 · 17:51

Neupath Health appoints Lemieux as CEO

Other Jan 26, 2026 · 07:30

NEUPATH HEALTH ANNOUNCES EXECUTIVE LEADERSHIP CHANGES AS PART OF PLANNED TRANSITION, PRE-ANNOUNCES STRONG 2025 RESULTS

Other Nov 13, 2025 · 07:30

NEUPATH HEALTH REPORTS THIRD QUARTER 2025 RESULTS

Other